A Cohort Study of Patients With Metastatic Colorectal Cancer Treated With Avastin® as First-line Therapy for Liver Metastases Considered as Potentially Resectable FRESH-PEF74087-en Camille BACHOT A Cohort Study of Patients With Metastatic Colorectal Cancer Treated With Avastin® as First-line Therapy for Liver Metastases Considered as Potentially Resectable PICASSO FRESH-PEF74087-en 74087 FRESH-PEF74087 NCT01343901 F. HOFFMANN-LA ROCHE AG Epidemiology France Portal (PEF) null ;Medical data center bevacizumab Gastroenterology Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues Healthcare system determinants: Use of care Healthcare system determinants Primary Objective: evaluate the efficacy and safety of bevacizumab as first-line treatment in participants with colorectal cancer and potentially resectable liver metastases. Secondary Objectives: - To describe patients’ characteristics treated with Avastin®, - To describe the subgroup of patients with unresected missing metastases, with or without surgery, - To describe criteria used to define unresectability, - To describe progression-free survival in all patients, - To describe relapse-free survival in all resected patients with no DMD, - To describe overall survival in all patients, - To describe histopathological response in resected patients, - To describe Avastin® treatment modalities, - To describe safety profile of Avastin®. null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Inclusion criteria: - Man or woman aged 18 years or over,Diagnosed with a colon or rectal adenocarcinoma including exclusively liver or liver and lung metastases, - For whom a first-line treatment with Avastin® was set up by a MDC in the context of potentially resectable metastatic disease, - Who has been informed orally and in writing about the study, its objectives and modalities of implementation and who did not object that the collected data were subject to an automated processing. Patient considered as upfront resectable at inclusion, - Patient considered as he/she could never be resectable, - Patient already enrolled in a clinical study for cytotoxic anticancer medication and/or innovative therapy. Clinical data Participant-reported health data CDISC like GCP/GVP Health event/morbidity Health event/mortality Other Through independent healthcare practitioners < 500 individuals Converting or copying information into a structured record Observational Study Observational Study Cohort study 218 Unknown Restricted access Access on specific project only